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Abstract
 
T cell–specific adaptor protein (TSAd) is a T lineage–restricted signaling adaptor molecule that
is thought to participate in the assembly of intracellular signaling complexes in T cells. Previous
studies of TSAd-deficient mice have revealed a role for TSAd in the induction of T cell inter-
leukin 2 secretion and proliferation. We now show that TSAd-deficient mice are susceptible to
lupus-like autoimmune disease. On the nonautoimmune-prone C57BL/6 genetic background,
TSAd deficiency results in hypergammaglobulinemia that affects all immunoglobulin (Ig)G
subclasses. Older C57BL/6 TSAd-deficient mice (1 yr of age) accumulate large numbers of
activated T and B cells in spleen, produce autoantibodies against a variety of self-targets including
single stranded (ss) and double stranded (ds) DNA, and, in addition, develop glomerulonephritis.
We further show that immunization of younger C57BL/6 TSAd-deficient mice (at age 2 mo)
with pristane, a recognized nonspecific inflammatory trigger of lupus, results in more severe
glomerulonephritis compared with C57BL/6 controls and the production of high titer ss and
ds DNA antibodies of the IgG subclass that are not normally produced by C57BL/6 mice in
this model. The development of autoimmunity in TSAd-deficient mice is associated with
defective T cell death in vivo. These findings illustrate the role of TSAd as a critical regulator
of T cell death whose absence promotes systemic autoimmunity.
Key words: apoptosis • autoimmunity • T lymphocyte • signal transduction • 
glomerulonephritis
 
Introduction
 
T cell–specific adapter protein (TSAd) is an SH2 domain–
containing intracellular adaptor-like molecule that is expressed
in thymocytes and activated mature T cells (1, 2). The exact
role played by TSAd in T cell signal transduction is un-
known. TSAd has been described to interact physically
with the Src family tyrosine kinase, Lck, the Tec family
tyrosine kinases, Rlk and Itk, and the MAP3 kinase,
MEKK2 (2–4). However, although these interactions can
be readily detected in yeast cells, it has been more difficult
to demonstrate binding in mammalian cells, particularly
between cell-endogenous proteins. Therefore, the signifi-
cance of interaction with these kinases is unclear. In fact,
recent studies have indicated that TSAd may function pre-
dominantly in the nucleus where it acts to positively regulate
the transcription of different T cell target genes, including
the gene for the T cell autocrine growth factor, IL-2 (5).
This would be consistent with the finding that splenic T
cells from TSAd-deficient mice secrete less IL-2 and prolif-
erate less upon TCR engagement in vitro (3).
In this study, we have further examined the immunological
function of TSAd-deficient mice. We found that TSAd-
deficient mice are susceptible to spontaneous and induced
lupus-like autoimmune disease. In addition, we found that
T cells from TSAd-deficient mice are resistant to antigen-
induced cell death in vivo, a process that is thought to prevent
the development of autoimmunity in healthy animals. These
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findings highlight the role of TSAd as a novel regulator of
T cell death and lupus-like autoimmunity.
 
Materials and Methods
 
Mice.
 
C57BL/6 TSAd-deficient mice were obtained from J.
Bluestone (University of California at San Francisco, San Fran-
cisco, CA) and were derived by backcrossing 129/Sv 
 
  
 
C57BL/6
TSAd-deficient mice (3) with C57BL/6 mice for eight genera-
tions. In these studies, we produced ninth generation C57BL/6
TSAd heterozygotes that were then intercrossed to generate litter-
mate C57BL/6 wild-type, heterozygote, and TSAd-deficient
mice for use in experiments. Most experiments were performed
with these littermate mice. For some experiments, C57BL/6 wild-
type and TSAd-deficient mice were generated from separate mat-
ings in our facilities. Additional C57BL/6 mice and control
MRL/lpr mice were purchased from Taconic Farms and The
Jackson Laboratory, respectively. Mice were housed and bred un-
der standard conditions. Serial serum samples taken from sentinel
mice in the colony as well as from the test mice directly were con-
sistently negative for common murine viral pathogens. All experi-
ments were performed in compliance with Hospital for Special
Surgery and University of Michigan guidelines and were approved
by the respective institutional animal care and use committees.
 
Pristane Administration.
 
C57BL/6 wild-type and TSAd-defi-
cient mice were given a single i.p. injection of 0.5 ml Pristane
(Sigma-Aldrich) at 2 mo of age. After 6 mo, the presence of au-
toantibodies in sera was determined and the mice were killed for
histopathological analysis.
 
Serology.
 
Serum total IgG, IgG subclass, and IgM concentra-
tions were determined by ELISA using an SBA Clonotyping™
System (Southern Biotechnology Associates, Inc.). Anti-cardio-
lipin antibodies were detected with the use of an anti-cardiolipin
ELISA kit (Sigma-Aldrich). Anti–double stranded (ds) DNA anti-
bodies and rheumatoid factor were detected using mouse anti–ds
DNA and rheumatoid factor ELISA kits (Alpha Diagnostic Inter-
national). Antibodies against single stranded (ss) DNA were de-
tected by ELISA as previously described (6). The secondary
detection reagents used in autoantibody ELISAs were goat anti–
mouse IgG (GAMIgG) or IgM coupled to alkaline phosphatase
(Sigma-Aldrich). To determine levels of nonspecific binding asso-
ciated with known IgG or IgM concentrations in test samples, se-
rial dilutions of normal mouse IgG or IgM were also assayed in
autoantibody ELISA experiments. Specific autoantibody binding
was thus determined by subtracting from the test sample OD
value, the OD value obtained with the same concentration of
normal IgG or IgM calculated from a standard curve. In these ex-
periments, test samples were scored positive if their specific OD
value was greater than an arbitrary 0.25 units.
To detect anti-nuclear antibodies and confirm the presence of
anti-ds DNA specificities, serum samples (1:100 dilution) were
incubated with fixed and permeabilized HEp-2 cells (Bion Enter-
prises, Ltd.) or 
 
Crithidia luciliae
 
 organisms (Wampole Laborato-
ries), respectively. Slides were washed and then incubated with
GAMIgG coupled to Alexa 488 (Molecular Probes). After further
washing and mounting, cells were viewed on a Nikon Eclipse
E600 fluorescent microscope.
 
Western Blotting.
 
Western blotting experiments were per-
formed as previously described using nuclear lysates prepared
from Jurkat T leukemia cells (5). Mouse sera were used at a dilu-
tion of 1:1,000 and the secondary detection reagent was
GAMIgG coupled to horseradish peroxidase (Santa Cruz Bio-
technology, Inc.).
 
Pathology.
 
Different organs from C57BL/6 wild-type, TSAd
heterozygote, and TSAd-deficient mice were fixed in formalin
and embedded in paraffin for histological studies. Sections were
stained with hematoxylin and eosin (H&E) and additionally peri-
odic acid-Schiff and hematoxylin (for kidneys only). For immu-
nohistochemistry, kidneys were quick frozen in OCT com-
pound. Kidney sections were first blocked by incubation in 10%
goat serum followed by incubation with GAMIgG Alexa 488 to
detect IgG deposited in glomeruli. Sections were viewed on a
Nikon Eclipse E600 microscope.
 
Staphylococcal enterotoxin B (SEB) Immunization.
 
Mice were
immunized i.p. with 50 
 
 
 
g SEB (Sigma-Aldrich). For T cell
death experiments, immediately before and at d 4 and 11 after
SEB immunization, 300–400 
 
 
 
l venous blood was collected from
mice by orbital bleeding and the percentage of TCR V
 
 
 
6
 
  
 
or
TCR V
 
 
 
8
 
  
 
T cells was determined (see below). To examine T
cell activation marker and cytokine expression, flow cytometric
analyses were performed upon splenic T cells 24 h after SEB ad-
ministration (see below).
 
Flow Cytometry.
 
The following labeled monoclonal antibod-
ies were used for flow cytometry: H57-597-CyChrome (TCR
 
 
 
chain), RA3-6B2-PE (CD45R/B220), H1.2F3-PE (CD69), Jo2-
FITC (CD95/Fas), MEL-14-FITC (CD62L), IM7-PE (CD44),
RR4-7-PE and FITC (TCR V
 
 
 
6), MR5-2-PE and FITC (TCR
V
 
 
 
8), GK1.5-FITC (CD4), JES6-5H4-PE (IL-2), XMG1.2-PE
(IFN-
 
 
 
), A95-1-PE (rat IgG2b isotype control for IL-2), and R3-
34-PE (rat IgG1 isotype control for IFN-
 
 
 
). All antibodies were
from BD Biosciences with the exception of XMG1.2-PE, which
was from Caltag. To enumerate percentages of TCR
 
  
 
  
 
T cells
and B cells in splenocyte populations, samples were double
stained with TCR
 
  
 
and B220 antibodies. Expression of activa-
tion markers (CD69, CD44, CD95, and CD62L) upon splenic
TCR
 
  
 
  
 
T cells from older mice was determined by double
staining of splenocytes with a TCR
 
  
 
antibody together with the
appropriate activation marker antibodies. The percentage of
TCR V
 
 
 
6
 
  
 
or TCR V
 
 
 
8
 
  
 
cells among CD4
 
  
 
T cells in periph-
eral blood of SEB-immunized mice was assessed by double stain-
ing with PE-labeled TCR antibodies and CD4-FITC. Likewise,
the percentage of TCR V
 
 
 
6
 
  
 
or TCR V
 
 
 
8
 
  
 
T cells that express
CD69, IL-2, and IFN-
 
  
 
in spleens of SEB-immunized mice was
determined by double staining using FITC-labeled TCR anti-
bodies. For IL-2 and IFN-
 
  
 
analyses, harvested splenocytes were
first restimulated with 50 ng/ml PMA and 500 ng/ml ionomycin
for 4 h and GolgiStop (BD Biosciences) was added for the last 2 h
of culture. Cells were then fixed and permeabilized with Cytofix/
CytoPerm reagent (BD Biosciences) before staining.
 
Gene Profiling.
 
CD4
 
  
 
T cells were purified from eight pooled
C57BL/6 wild-type and eight pooled C57BL/6 TSAd-deficient
spleens (from mice aged 2 mo) using mouse CD4 Dynabeads and
DETACHaBEAD mouse CD4 reagent (Dynal) according to the
manufacturer’s instructions. As determined by flow cytometry,
CD4
 
  
 
T cells were 
 
 
 
98% pure and were not activated as a result
of the isolation procedure. CD4
 
  
 
T cells were not stimulated or
were stimulated by culture for 20 h in the wells of 12-well tissue
culture plates that had been precoated with 2 
 
 
 
g/ml of the 145-
2C11 anti-CD3 antibody (BD Biosciences). Cells were plated at a
density of 2.5 
 
  
 
10
 
6
 
/ml and the total well volume was 2 ml. Sol-
uble 37.51 anti-CD28 antibody was included in the culture me-
dium at 2 
 
 
 
g/ml. Total RNA was prepared from unstimulated
and stimulated CD4
 
  
 
T cells using RNeasy Mini Kits (QIAGEN)
and T7-dT primed ds cDNA was synthesized using a SuperScript
Choice System (Invitrogen). Biotinylated cRNA was prepared
with the use of T7 BioArray High Yield RNA Transcript Label-T
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ing Kit (Enzo Diagnostics). 15 
 
 
 
g fragmented cRNA was incor-
porated into cocktails that were hybridized with U74Av2 arrays
(Affymetrix, Inc.) containing probe sets representing 
 
 
 
12,000
distinct murine genes. All hybridization, washing, and staining
procedures were performed according to the manufacturer’s in-
structions.
Data were analyzed with the use of Affymetrix Suite (Affyme-
trix, Inc.) and GeneSpring (Silicon Genetics) software. To assist
in the identification of genes that were positively or negatively
regulated by TSAd, we applied several restrictions to data. First,
because TSAd is up-regulated upon T cell activation, we selected
genes that were increased (positive regulation) or decreased (neg-
ative regulation) at least threefold in wild-type T cells in response
to CD3/CD28. Second, because TSAd would be expected to ex-
ert a greater influence upon gene expression in stimulated versus
unstimulated T cells (based on increased expression) we selected
genes in which the ratio of gene expression between stimulated
wild-type and knockout T cells was greater than (positive regula-
tion) or less than (negative regulation) the ratio of gene expres-
sion between unstimulated wild-type and knockout T cells by at
least 1.5-fold. Third, because TSAd would be predicted to influ-
ence gene expression at least in stimulated T cells, we only con-
sidered genes that were decreased (positive regulation) or in-
creased (negative regulation) by a factor of 1.5-fold in stimulated
knockout T cells relative to stimulated wild-type T cells. Fourth,
so as to increase the reliability of results, we considered only those
genes that were assigned as present (P) by Affymetrix in stimu-
lated wild-type T cells (for positively regulated genes) or in stim-
ulated knockout T cells (for negatively regulated genes).
 
Online Supplemental Material.
 
Fig. S1, which shows total se-
rum Ig levels by mouse gender, and Tables S1–S8, which depict
raw data values of TSAd positively regulated genes in microarray
experiments, are available at http://www.jem.org/cgi/content/
full/jem.20021358/DC1.
 
Results
 
Hypergammaglobulinemia in TSAd-deficient Mice.
 
As part
of an effort to examine in more detail the immunological
characteristics of TSAd-deficient mice, we assayed serum Ig
concentrations. Altered serum Ig concentrations could indi-
cate a role for TSAd in the generation of appropriate T cell
help for B cell antibody responses. Serum IgG and IgM lev-
els in C57BL/6 TSAd-deficient and littermate control wild-
type and TSAd heterozygote mice were determined by
ELISA (Fig. 1). In comparison with wild-type mice, TSAd-
 
deficient mice showed elevated levels of serum IgG (up to
threefold) at all ages examined starting from 2 mo. In addi-
tion, IgM levels in TSAd-deficient mice were elevated (up
to twofold) starting at 3–4 mo of age. In contrast, heterozy-
gote TSAd mice, showed only small increases in serum IgG
and essentially no increases in IgM compared with wild-type
mice. Hypergammaglobulinemia in TSAd-deficient mice
was independent of mouse gender (see Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20021358/DC1).
All subclasses of IgG were elevated in TSAd-deficient mice
suggesting a lack of bias toward either Th1 or Th2 differen-
tiation programs in these animals (Fig. 1).
 
TSAd-deficient Mice Develop Antinuclear Antibodies (ANA).
 
Hypergammaglobulinemia is encountered commonly in
mouse models of lupus-like systemic autoimmune disease
(7, 8). One such classic model of lupus-like autoimmunity
is the MRL/lpr mouse (8). MRL/lpr mice develop a severe
lupus-like disease with 50% mortality by 6 mo of age. Hy-
pergammaglobulinemia in TSAd-deficient mice was not as
pronounced as in MRL/lpr mice (of 12 examined MRL/
lpr mice aged 3–6 mo, mean IgG levels were 4.62 mg/ml
with a SE of 0.71 mg/ml) but was comparable to that seen
in other mouse lupus models such as NZB/W and BXSB
mice (7). Therefore, to determine if TSAd-deficient mice
also succumb to systemic autoimmunity, we first assayed
sera for the presence of ANA. ANA were detected by im-
munofluorescent staining of permeabilized HEp-2 epithe-
lial cells (Fig. 2, A and B). At all ages examined, from 2 up
to 12–14 mo, the percentage of sera that were ANA
 
  
 
was
significantly higher in TSAd-deficient mice than in litter-
mate control wild-type and TSAd heterozygote mice (Fig.
2 A). At 12–14 mo, 11 out of 16 (69%) TSAd-deficient
mice showed ANA reactivity compared with 11 out of 12
(92%) MRL/lpr mice at 3–6 mo of age. There were no ob-
vious sex differences in the propensity of TSAd-deficient
mice to develop ANA. A variety of different patterns of an-
tinuclear reactivity were observed in TSAd-deficient mice,
each of which has been noted previously in human SLE
(9). These included homogenous nuclear reactivity with or
without cytoplasmic dots, nuclear rim staining, and nucle-
olar staining, again, with or without cytoplasmic dots (Fig.
2 B). These findings are consistent with reactivity against
nuclear and ribosomal proteins and/or nucleic acids. To
Figure 1. Serum Ig levels in
TSAd-deficient mice. Concentra-
tions of total IgG, IgM, and different
IgG subclasses in sera from TSAd-
deficient (   ) and littermate control
wild-type ( / ) and TSAd het-
erozygote ( / ) mice at the indi-
cated ages were determined by
ELISA (IgG subclass analyses were
performed upon 3–4-mo-old mice).
Data are represented as mean plus 1
SE. Except for IgM at 2 mo, all increases in Ig concentration in TSAd-deficient mice (relative to wild-type mice) are statistically significant (all P   0.05
using Student’s two-sample t test). Increases in Ig concentrations seen in TSAd heterozygotes (relative to wild-type) are statistically significant only for
IgG at 2 and 3–4 mo. Within each genotype and age group category mixed numbers of males and females were analyzed (total numbers are shown in
parentheses above bars). Increases in Ig concentrations seen in TSAd-deficient mice were independent of gender (see Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20021358/DC1).T
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confirm that sera from TSAd-deficient mice contained an-
tinuclear protein specificities, we examined sera for their
reactivity with nuclear lysates prepared from T leukemia
cells in Western blotting experiments (Fig. 2 C). When
compared with sera from control wild-type mice, sera from
older ANA
 
  
 
TSAd-deficient mice were seen to react
strongly and heterogeneously with a number of different
nuclear proteins.
 
Autoantibody Specificities in TSAd-deficient Mice.
 
Anti-
bodies against ss DNA, ds DNA, cardiolipin, and IgG
(rheumatoid factor) are found commonly in sera of lupus-
prone mice and human SLE patients (7, 8, 10–12). There-
fore, we examined TSAd-deficient sera for the presence of
these autoantibodies by ELISA. Up to 9 mo of age, anti-
bodies against each of these antigens were rarely detected.
After 9 mo, however, all four specificities were detected in
Figure 2. ANA in sera from TSAd-defi-
cient mice. (A) The presence of ANA anti-
bodies in sera from TSAd-deficient and
littermate control wild-type and TSAd het-
erozygote mice was determined by immu-
nofluorescent staining of HEp-2 epithelial
cells. Shown is the percentage of ANA 
sera for each genotype at the indicated ages
(total numbers of mice analyzed are shown
in parentheses). Differences between
TSAd-deficient and wild-type control mice
are statistically significant in all age groups
(all P   0.05 calculated using the chi-squared test of independence). nd, not determined. (B) Different patterns of nuclear staining of HEp-2 epithelial
cells observed with TSAd-deficient sera. Clockwise from top left: homogenous nuclear, rim, homogenous nuclear with cytoplasmic dots, and nucleolar
with cytoplasmic dots. (C) Reactivity of sera from four 7–9-mo-old ANA  TSAd-deficient mice and age-matched control wild-type (wt) mice with
proteins in nuclear lysates of T leukemia cells as detected by Western blotting. The wild-type serum was pooled from three different wild-type mice.
Figure 3. Reactivity of TSAd-
deficient sera with self-antigens. (A)
The presence of IgG antibodies
against ss DNA, ds DNA, cardio-
lipin, and IgG in sera from 1-yr-old
TSAd-deficient (n    19), 1-yr-old
control C57BL/6 wild-type (n   18,
except for anti-ss DNA where n   
20), and 3–6-mo-old MRL/lpr (n  
12) mice was determined by ELISA.
Sera were tested at a dilution of 1:50
and were scored positive based on
criteria outlined in Materials and
Methods. Shown is the percentage
of positive sera for each autoantigen.
Differences between TSAd-deficient
and C57BL/6 mice are statistically
significant for all autoantigens (all
P   0.05 determined using the chi-
squared test). (B) Representative
staining of Crithidia luciliae by TSAd-
deficient sera that scored positive for
anti-ds DNA antibodies by ELISA.
Shown is intense staining of the ds
DNA-containing kinetochore and
the dimmer staining nucleus. Reac-
tivity with the kinetochore (which is
free of ss DNA and not complexed
to protein) confirms the presence of
anti-ds DNA antibodies. (C) Titers
of autoantibodies in TSAd-deficient
and MRL/lpr mice. Reactivity of
diluted sera from seven 1-yr-old
TSAd-deficient mice and six 4–6-
mo-old MRL/lpr mice with the in-
dicated autoantigens was determined
by ELISA as indicated in A. Data
from individual mice are represented
by different symbols. For each
mouse the same symbol is used for
each antigen.T
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the sera of TSAd-deficient mice, although rarely in the
sera of control wild-type mice (Fig. 3 A). We compared
TSAd-deficient sera with MRL/lpr sera for frequency and
titer of the different autoantibody specificities (Fig. 3, A
and C). Notably, the frequency of anti-ss DNA antibodies
was lower in TSAd-deficient mice compared with MRL/
lpr mice (37 vs. 75%, respectively). However, the fre-
quency of anti-ds DNA, anticardiolipin, and rheumatoid
factor antibodies was only slightly decreased or not at all
decreased in TSAd-deficient mice compared with MRL/
lpr mice (26 vs. 42%, 58 vs. 42%, and 42 vs. 42%, respec-
tively; Fig. 3 A). Furthermore, whereas titers of anti-ss
DNA antibodies were lower in TSAd-deficient mice, ti-
ters of anti-ds DNA and anticardiolipin antibodies were
comparable between TSAd-deficient and MRL/lpr mice
and titers of rheumatoid factor antibodies were higher in
the TSAd-deficient mice (Fig. 3 C). For individual TSAd-
deficient mice (and MRL/lpr mice), the presence or titer
of antibodies against one target was not necessarily predic-
tive of the presence or titer of antibodies against another
target, thus emphasizing the heterogeneity of the autoanti-
body response (Fig. 3 C).
 
Kidney Disease and Lung Leukocytic Infiltration in TSAd-
deficient Mice.
 
In lupus-like syndromes, immune com-
plexes become deposited in kidney glomeruli leading to
glomerulonephritis (7, 8, 10, 11). To determine if TSAd-
deficient mice develop glomerulonephritis, older mice
were killed and kidneys were subject to histopathological
and immunohistochemical analyses. Kidneys from control
wild-type mice revealed glomeruli with normal cellularity,
mesangium, and glomerular basement membranes (Fig. 4 A
and Table I). In contrast, kidneys of TSAd-deficient mice
were frequently abnormal and showed signs of glomerulo-
nephritis (Fig. 4 A and Table I). These included a marked
increase in glomerular size and cellularity (accounted for by
an increase in the number of mesangial cells and by the
presence of inflammatory cells, including polymorphonu-
clear leukocytes), an increase in the amount of mesangial
matrix, a thickening of glomerular basement membranes,
and the presence of intratubular proteinaceous hyaline casts
Figure 4. Kidney and lung pathology of TSAd-deficient
mice. (A and B) H&E stained kidney sections from 1-yr-
old control wild-type and TSAd-deficient mice. Repre-
sentative glomeruli are shown in A. Note gross increase in
mesangial cellularity in TSAd-deficient glomeruli. (B) In-
tratubular hyaline casts (indicated by arrows) seen in
TSAd-deficient kidneys. (C) IgG immune complex depos-
its in glomeruli of a 9-mo-old TSAd-deficient mouse de-
tected by immunofluorescence. (D) H&E stained lung sec-
tions from 1-yr-old control wild-type and TSAd-deficient
mice. Note perivascular inflammatory aggregate (indicated
by arrow) and thickening of alveolar interstitial spaces in
the TSAd-deficient lung.T
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indicative of glomerular dysfunction (Fig. 4 B). Further-
more, IgG immune complex deposits were detected in
glomeruli (Fig. 4 C). These features were qualitatively and
quantitatively similar to those observed in kidneys of 5–6-
mo-old MRL/lpr mice with the exception that glomeruli
in TSAd-deficient kidneys showed little evidence of sclero-
sis (not depicted and references 6–8). None of the changes
observed in kidneys of TSAd-deficient mice were apparent
 
Table I.
 
Glomerular Pathology of TSAd (
 
   
 
) and TSAd (
 
   
 
) Mice
 
a
 
Mouse Genotype Pristane
 
b
 
Age (mo) Sex
 
c
 
Mesangial
hypercellularity
Mesangial
matrix increase
Basement
membrane thickness
WT1
 
   
 
No 12 F 0 0 0
WT2
 
   
 
No 12 F 0 0 0
WT3
 
   
 
No 13 F 0 0 0
WT4
 
   
 
No 12 M 0 0 0
WT5
 
   
 
No 13 M 0 0 0
K1
 
   
 
No 11 F 4 2 1
K2
 
   
 
No 14 F 1 1 1
K3
 
   
 
No 13 F 1 0 1
K4
 
   
 
No 12 F 4 2 3
K5
 
   
 
No 13 F 2 2 1
K6
 
   
 
No 13 F 1 2 1
K7
 
   
 
No 11 M 2 1 0
K8
 
   
 
No 13 M 1 1 0
K9
 
   
 
No 13 M 0 1 0
K10
 
   
 
No 13 M 1 1 1
K11
 
   
 
No 13 M 2 2 1
K12
 
   
 
No 13 M 1 1 0
WTP1
 
   
 
Yes 8 F 0 0 0
WTP2
 
   
 
Yes 8 F 1 1 1
WTP3
 
   
 
Yes 8 F 1 1 0
WTP4
 
   
 
Yes 8 F 1 1 0
WTP5
 
   
 
Yes 8 F 1 1 1
WTP6
 
   
 
Yes 8 F 1 1 0
WTP7
 
   
 
Yes 8 M 0 0 0
WTP8     Yes 8 M 0 0 0
WTP9     Yes 8 M 1 2 1
WTP10     Yes 8 M 1 1 1
WTP11     Yes 8 M 0 1 0
WTP12     Yes 8 M 1 1 1
WTP13     Yes 8 M 1 1 0
KP1     Yes 8 F 2 2 1
KP2     Yes 8 F 4 4 3
KP3     Yes 8 F 1 2 3
KP4     Yes 8 F 3 3 3
KP5     Yes 8 M 1 1 0
KP6     Yes 8 M 3 3 3
KP7     Yes 8 M 3 3 3
KP8     Yes 8 M 2 3 2
aGlomeruli were scored in a blinded fashion on a 0–4 scale for the indicated parameters. 0, normal; 4, pronounced change. Scores are based upon
analysis of 30–40 glomeruli in each kidney section.
bPristane was administered to mice at 2 mo of age. Analysis was performed at 8 mo.
cM, male; F, female.T
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in kidneys of TSAd heterozygote mice (unpublished data).
Consistent with the kidney pathology, the majority of
older TSAd-deficient mice showed evidence of pro-
teinuria. Of 19 examined 1-yr-old TSAd-deficient mice,
12 had urine protein levels in the range of 30 mg/dL and 4
had urine protein levels in the range of 100 mg/dL. Only
three mice showed the trace urine protein levels found in
wild-type mice (P   5   10 7 using the chi-squared test).
Another common feature of lupus-like syndromes is the
invasion of nonlymphoid organs by leukocytes (7, 8).
Therefore, we examined a number of different nonlym-
phoid tissues from older TSAd-deficient mice for evidence
of leukocytic infiltration. Particularly in lung, there were
large perivascular accumulations of leukocytes that were not
observed in control mice (Fig. 4 D). These leukocytic infil-
trates extended deep into the pulmonary parenchyma. In
addition, there was a thickening of interstitial alveolar spaces
and the fine alveolar architecture observed in control mice
was lost in the TSAd-deficient mice. Leukocytic infiltrates
were less frequently observed in other nonlymphoid organs.
Susceptibility of TSAd-deficient Mice to Experimentally
Induced Lupus-like Disease. Because several of the key lu-
pus-like disease features of TSAd-deficient mice are only
observed in older mice, we next asked if younger TSAd-
deficient mice are more susceptible to experimentally in-
duced lupus. To examine this, we immunized 2-mo-old
mice with the isoprenoid alkane, pristane, which has been
shown previously to act as a nonspecific inflammatory trig-
ger of lupus (13–15). We took advantage of the fact that
compared with other strains, C57BL/6 mice mount a
weaker autoimmune response to pristane that is not, for
example, accompanied by the production of IgG isotype
anti-ss DNA or anti-ds DNA antibodies (15–17). Confirm-
ing these previous reports, 6 mo after immunization with
pristane, C57BL/6 wild-type mice produced low titers of
IgM anti-ss DNA antibodies (11 out of 13 mice) but essen-
tially failed to produce IgG anti-ss DNA antibodies and
IgM and IgG anti-ds DNA antibodies (Fig. 5; low titers of
these antibodies were detected in 1 or 2 out of 13 wild-
type mice). In contrast, C57BL/6 TSAd-deficient mice
produced higher titer IgM anti-ss DNA antibodies and, in
addition, produced IgG anti-ss DNA antibodies (10 out of
10 mice) and IgM and IgG anti-ds DNA antibodies (9 and
4 out of 10 mice, respectively) after immunization with
pristane (Fig. 5).
We also examined kidneys of pristane-immunized mice
for evidence of glomerulonephritis (Table I). 6 mo after
pristane immunization, kidneys of wild-type pristane-
immunized mice showed histological evidence of only mild
glomerulonephritis. In contrast, kidneys of pristane-immu-
nized TSAd-deficient mice showed clear evidence of more
severe glomerulonephritis that was manifest as increased
mesangial hypercellularity, mesangial matrix deposition,
and glomerular basement membrane thickness. In accor-
dance with these findings, TSAd-deficient mice showed
evidence of increased proteinuria. Thus, of 10 examined
TSAd-deficient mice, 6 mo after pristane immunization, 6
had urine protein concentrations in the 30 mg/dL range
and 4 had urine protein concentrations in the 100 mg/dL
range. In comparison, of 13 examined wild-type mice at
the same time point, all had urine protein concentrations in
the 30 mg/ml range (P   5   10 5).
Lymphoid Hyperplasia in TSAd-deficient Mice. Next, we
examined whether lymphoid organs of TSAd-deficient
mice contain increased numbers of T cells that could point
to deregulated T cell function as a cause of autoimmunity.
However, it was previously reported that primary and sec-
ondary lymphoid organs from TSAd-deficient mice con-
tained normal numbers and ratios of T cells as well as B
cells (3). Therefore, during our analysis of TSAd-deficient
mice we reexamined this issue in case subtle differences had
been overlooked in the original studies (Table II). Indeed,
comparison of spleen weights between 29 control wild-
type mice and 30 TSAd-deficient mice, aged 2–3 mo, re-
vealed mild splenomegaly in the TSAd-deficient mice (an
 1.6-fold increase in spleen weight). Similarly, thymus
weight was notably increased in TSAd-deficient mice.
These increased spleen and thymus weights were associated
with increased cellularity. For spleen, the hypercellularity
affected both T and B compartments. For thymus, as re-
ported previously (3), no alterations in the ratios of CD4/
CD8 double negative, double positive, or single positive
thymocytes were noted (not depicted).
Figure 5. Pristane induction of anti-DNA antibodies in TSAd-defi-
cient mice. Control wild-type and TSAd-deficient mice were immunized
with pristane at 2 mo of age. 6 mo after immunization, the presence of
the indicated anti-DNA antibodies in sera was determined by ELISA. All
sera were tested at a dilution of 1:100. Data points represent different in-
dividual mice of the indicated genotypes. The difference in mean OD
value for IgM anti-ss DNA antibodies between wild-type and TSAd-defi-
cient mice is statistically significant (P   3.6   10 4 determined using the
Student’s two-sample t test). Differences between wild-type and TSAd-
deficient mice with respect to the percentage of mice that develop the
other types of anti-DNA antibodies (see text and Materials and Methods)
are also statistically significant (all P   5   10 5 determined using the chi-
squared test).T
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T Cells from Older TSAd-deficient Mice Display an Activated
Phenotype. By 9 mo of age, splenomegaly in TSAd-defi-
cient mice was more pronounced (Fig. 6 A). Furthermore,
histological examination of spleens and lymph nodes from
older TSAd-deficient mice revealed hyperreactive features.
There was an effacement of architecture seen as a lack of
clear distinction between red and white pulp areas in spleen
or between cortical and medullary areas in lymph nodes
(Fig. 6 B). To determine if T cells in older TSAd-deficient
spleens were in an activated state, splenocytes were double
stained with TCR   antibodies and different activation
marker antibodies (Fig. 6 C). In comparison with T cells
from spleens of control mice, T cells from TSAd-deficient
mice showed increased expression of CD69, CD44, and
Table II. Lymphoid Organ Weights and Lymphocyte Numbers in TSAd (   ) and TSAd (   ) Mice
TSAd (   ) TSAd (   )P a
Spleen weight (mg)b 61.2   1.9 98.2   6.1  4.8   10 7
Total spleen cell number 73.3   4.9   106 120.1   10.9   106  2.0   10 3
Percentage T cells 32.7   1.4 26.3   1.2  5.3   10 3
Total T cell number 23.7   1.2   106 31.0   2.0  4.8   10 3
Percentage B cells 55.9   1.2 60.0   2.0  1.0   10 1
Total B cell number 41.2   3.5   106 71.8   6.2   106  9.8   10 4
Thymus weight (mg) 57.0   4.0 79.9   4.3  2.0   10 3
Shown are mean values   1 SE.
aProbabilities were calculated using the Student’s two-sample t test.
bSpleen figures are derived from 29 TSAd (   ) and 30 TSAd (   ) mice, aged 2–3 mo. All other figures are based upon data from 7 TSAd
(   ) and 7 TSAd (   ) mice, aged exactly 8 wk.
Figure 6. Splenic pathology of
TSAd-deficient mice. (A) Top:
spleens from 9-mo-old wild-type
(left) and TSAd-deficient (right)
mice. Middle: spleen weights of
six 1-yr-old wild-type and
TSAd-deficient mice. Bottom:
the total number of T cells and B
cells in spleens from three 1-yr-old
wild-type and TSAd-deficient
mice were determined. (B) H&E
stained spleen and inguinal
lymph node sections from 1-yr-
old wild-type and TSAd-deficient
mice. Note the loss of normal ar-
chitecture (clearly defined areas
of red and white pulp in spleen
and cortical and medullary re-
gions in lymph node) in TSAd-
deficient mice. (C) Expression of
the indicated activation markers
on splenic T cells from 9-mo-old
wild-type (blue or green) and
TSAd-deficient (red) mice was
determined by flow cytometry.T
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CD95/Fas activation markers and decreased expression of
CD62L/l-selectin (whose expression correlates inversely
with activation status). The same results were obtained
with all 11 tested TSAd-deficient mice age 9–13 mo. In
contrast, T cells from older TSAd heterozygotes did not
show increased expression of CD69, CD44, or CD95, nor
decreased expression of CD62L (not depicted). Similar to
T cells, B cells from older TSAd-deficient spleens showed
increased expression of CD69, CD44, and CD95 although
up-regulation of these activation markers on B cells was less
dramatic (not depicted). In summary, these findings indi-
cate that older TSAd-deficient spleens contain large num-
bers of activated T and B cells.
Defective T Cell Death in TSAd-deficient Mice. We con-
sidered the possibility that the development of autoimmu-
nity in TSAd-deficient mice was consequent to a failure of
antigen-induced T cell death that would be consistent with
the spleen findings. To examine this, control wild-type and
TSAd-deficient mice were immunized with the superanti-
gen, SEB. In healthy animals, immunization with SEB leads
to a reduction in the number of responding TCR V 8  T
cells from the peripheral T cell pool as they die by apoptosis
(18). To examine whether TCR V 8  T cells are as effi-
ciently eliminated in TSAd-deficient mice, we determined
the percentage of V 8  T cells amongst total CD4  periph-
eral blood T cells at different time points after SEB immuni-
zation (Fig. 7 A). In control mice, immunization with SEB
led to a time-dependent decrease in the percentage of V 8 
T cells that was specific to V 8  T cells because the per-
centage of V 6  T cells was not significantly altered in these
experiments. Likewise, in TSAd-deficient mice, immuniza-
tion with SEB led to a reduction in the percentage of V 8 
T cells and not V 6  T cells. However, elimination of
V 8  T cells in TSAd-deficient mice was clearly less effi-
cient than in the controls. The same results were obtained
in two identical repeat experiments. Importantly, the slower
kinetics of T cell elimination in TSAd-deficient mice could
not be explained on the basis that the initial activation of
V 8  T cells in response to SEB is impaired in these ani-
mals. Thus, V 8  T cells from TSAd-deficient and control
wild-type mice were induced to express comparable levels
of the CD69 activation marker when examined 24 h after
immunization with SEB (Fig. 7 B). In addition, up to 3 d
after SEB immunization, V 8  T cells from TSAd-deficient
and wild-type mice were seen to undergo the same number
of cell divisions in vivo (unpublished data).
Microarray Analysis of TSAd-regulated Gene Transcrip-
tion. The Fas death receptor pathway has been studied ex-
tensively as a major pathway involved in the control of T
cell death (19–21). In in vitro studies, TSAd-deficient T
cells showed partial resistance to Fas-mediated apoptosis that
was not associated with reduced expression of either Fas or
Fas ligand (unpublished data). However, the significance of
these findings to the impaired T cell death seen in TSAd-
deficient mice in vivo is uncertain because recent studies
have indicated that superantigen-induced T cell death is Fas
independent (22–24). Therefore, to shed light upon possible
mechanisms by which TSAd might regulate T cell death,
we undertook gene profiling experiments to determine in
total which genes are regulated by TSAd in activated T
cells. In these experiments we compared gene expression
between purified wild-type and TSAd-deficient CD4  T
cells that were either not stimulated or stimulated for 20 h
with a CD3 antibody (directed against the TCR complex)
plus an antibody against the CD28 T cell costimulatory re-
ceptor. To uncover genes that were positively or negatively
regulated by TSAd, several filters were placed upon the data
derived from these experiments (refer to Materials and
Methods). With the use of these filters, we identified a total
of 107 genes (out of  12,000) that were positively regu-
Figure 7. Defective T cell death in TSAd-deficient
mice. (A) Percentages of TCR V 6  or TCR V 8  T
cells amongst total CD4  T cells in venous blood from
wild-type and TSAd-deficient mice (age 2 mo) at the indi-
cated times after immunization with SEB were determined
by flow cytometry. Data are from eight mice in each group
and are represented as means   1 SE. At days 4 and 11 dif-
ferences between wild-type and TSAd-deficient mice with
respect to the percentage of V 8  T cells are statistically
significant (both P   0.005 calculated using the Student’s
two sample t test). (B) CD69 expression on TCR V 6 
and V 8  T cells from wild-type and TSAd-deficient mice
24 h after immunization with SEB was determined by flow
cytometry. The percentages of V 6  and V 8  T cells that
express CD69 are indicated in parentheses.T
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lated by TSAd in CD4  T cells (Fig. 8). In contrast, using
the same filters, we did not identify any genes that were
negatively regulated by TSAd. Within the group of posi-
tively regulated genes, several have been previously ascribed
a proapoptotic function in different cell types. These in-
clude the transmembrane protein, BAP29 (25), the intracel-
lular chloride channel, CLIC4 (26), the proto-oncogene,
c-myc (27), the molecular chaperone, Hsp60 (28), and IFN- 
(29). Furthermore, confirming earlier findings, IL-2 was
identified as a major positively regulated TSAd target gene
Figure 8. Genes positively regulated by TSAd in CD4  T cells. Purified CD4  splenic T cells from 2-mo-old wild-type (WT) and TSAd-deficient
(KO) mice were not stimulated (0) or stimulated with CD3 plus CD28 antibodies for 20 h (20) in vitro. Relative gene expression in unstimulated and
stimulated T cells was determined in gene profiling experiments using Affymetrix U74Av2 microchips. Shown are those genes (107 total out of
 12,000) where WT (20)   WT (0) by a factor of at least threefold, WT (20)/KO (20)   WT (0)/KO (0) by at least 1.5-fold, and WT (20)   KO (20)
by at least 1.5-fold. Genes are categorized on the basis of known or inferred (based on amino acid sequence homology) function. For each gene the WT/KO
ratio at 20 h is depicted. For all data values for this gene set see Tables S1–S8, available at http://www.jem.org/cgi/content/full/jem.20021358/DC1.T
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in these experiments. Although IL-2 is known to function
as a T cell growth factor in vitro, numerous studies have
shown that IL-2 acts only to promote T cell death in vivo
(30–34). Thus, impaired induction of IL-2 in vivo could be
an important factor accounting for the resistance of TSAd-
deficient T cells to apoptotic death. Given these findings,
therefore, we sought to verify that TSAd-deficient T cells
produce less IL-2 protein in vivo. For this, we examined
IL-2 protein levels in V 8  splenic T cells 24 h after immu-
nization of mice with SEB using an intracellular staining
technique. As shown in Fig. 9, TSAd-deficient V 8  T
cells synthesized considerably less IL-2 protein (and IFN- )
in response to SEB as determined in three repeat experi-
ments. In contrast, for the other apoptosis-related genes, we
were unable to detect any differences in protein expression
despite the changes in mRNA levels (unpublished data).
Thus, TSAd-deficient T cells produce less IL-2 in vivo as
well as in vitro, which may account for the development of
systemic autoimmunity in these animals.
Discussion
The main finding of these studies is that TSAd-deficient
mice develop spontaneously with age a systemic lupus-like
autoimmune disease that involves hypergammaglobuline-
mia, production of autoantibodies against different targets
including ss and ds DNA, lymphoid hyperplasia, accumula-
tion of large numbers of activated lymphocytes, leukocytic
infiltration of nonlymphoid organs, and glomerulonephritis.
These features are similar to those seen in the NZB/W
mouse and the Fas-deficient MRL/lpr mouse, although the
disease in TSAd-deficient mice is less severe than in these
classical models of mouse lupus. Disease in MRL/lpr and
NZB/W mice is characterized by early production of au-
toantibodies, acute renal failure, and early death that affects
females more than males (7, 8). In contrast, disease in
TSAd-deficient mice is later in onset, does not result in sig-
nificantly increased mortality up to 15 mo (unpublished
data), and does not affect females preferentially. In this re-
gard, the disease in TSAd-deficient mice is more akin to the
lupus-like disease that occurs in several other genetically en-
gineered mouse models such as cbl-b, stra13, and bim-defi-
cient mice, CD45E613R knock-in mice, and bcl-2 trans-
genic mice where significant early mortality has not been
reported and/or sex differences are not apparent (35–39).
Several factors could account for the prolonged lifespan
of TSAd-deficient mice despite the development of marked
glomerulonephritis. Most notable of these is the absence of
a vasculitic response in TSAd-deficient mice. Vasculitis oc-
curs in both MRL/lpr and NZB/W mice and in the former
at least contributes in a major way to early mortality (6–8).
It should also be noted that the spontaneous autoimmune
disease that results from TSAd deficiency described herein is
observed on the C57BL/6 genetic background. In compar-
ison with other strains, C57BL/6 mice are less prone to de-
velop lupus-like autoimmunity (16, 40, 41). For example,
young wild-type C57BL/6 mice are relatively resistant to
pristane-induced lupus compared with other strains. How-
ever, further illustrating the fact that impaired expression of
TSAd promotes systemic autoimmunity is the finding here
that young C57BL/6 TSAd-deficient mice are highly sus-
ceptible to pristane-induced lupus.
T cells from TSAd-deficient mice were shown to be re-
sistant to superantigen-induced death in vivo. This finding
is highly significant, pointing to the mechanism by which
TSAd-deficient mice develop autoimmunity. Superantigen-
induced T cell death is known to involve mitochondrial
dysfunction rather than death receptors (22–24). This im-
plies that the mitochondrial death pathway is impaired in
TSAd-deficient T cells. In turn, it has been shown previ-
ously that impaired mitochondrial death in T cells results in
systemic autoimmunity (23, 24, 42). It is also possible that
an observed partial resistance of T cells to Fas-mediated
death in vitro is relevant to the development of autoimmu-
nity in TSAd-deficient mice. Although Fas plays little role
in superantigen-induced T cell death, Fas is known to be
involved in the death of T cells that are reactive with persis-
tent self-antigens, thus accounting for the development of
autoimmunity in Fas-deficient MRL/lpr mice (7, 8, 42).
However, there are several counter-arguments to the no-
tion that Fas-mediated apoptosis is significantly impaired in
C57BL/6 TSAd-deficient mice in vivo or that impaired
Fas-mediated apoptosis contributes to autoimmune disease.
First, C57BL/6/lpr mice, in contrast to MRL/lpr mice, do
not develop significant lupus-like disease characterized by
the production of anti-DNA antibodies and the develop-
ment of glomerulonephritis (40, 41). Second, Fas-deficient
mice, regardless of background strain, acquire a large popu-
lation of CD4  CD8  (double negative) B220  peripheral T
Figure 9. Impaired cytokine production by TSAd-deficient T cells in
vivo. Control wild-type and TSAd-deficient mice were immunized with
SEB. After 24 h, IL-2 and IFN-  expression in V 8  splenic T cells was
determined by intracellular staining and flow cytometry. Filled and open
histograms represent isotype control and anticytokine-stained V 8  T
cells, respectively. The percentages of cytokine  V 8  T cells are indi-
cated in parentheses.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Lupus-like Autoimmunity in TSAd-deficient Mice 820
cells that are not seen in TSAd-deficient mice (7, 8). Third,
C57BL/6 Fas-deficient and Fas ligand–deficient mice are
more resistant to pristane-induced lupus than C57BL/6
controls, which is in contrast to C57BL/6 TSAd-deficient
mice, which are more susceptible (see above; 17).
Previous studies have indicated that TSAd can function as
a transcriptional regulator in T cells (5). Therefore, we per-
formed microarray experiments to identify any proapoptotic
or antiapoptotic genes that might be down-regulated or up-
regulated, respectively, in TSAd-deficient T cells. Several
genes that encode proapoptotic proteins were found to be
down-regulated in TSAd-deficient T cells. Prominent
amongst these was the gene for IL-2, thus confirming that
TSAd is a major regulator of this cytokine. Indeed, because
IL-2 is known to function as a major T cell growth factor in
vitro, reduced expression of many of the other genes identi-
fied in these microarray experiments, such as those encod-
ing DNA polymerases, cell cycle proteins, and metabolic
enzymes, might be consequent to deficient expression of
IL-2. However, despite the fact that IL-2 can act as a T cell
growth factor in vitro, IL-2 acts mainly as an inducer of T
cell death in vivo. Consequently, T cells from IL-2 and IL-
2R–deficient mice are resistant to superantigen-induced
death in vivo and, similar to TSAd-deficient mice, IL-2 and
IL-2R–deficient mice develop generalized autoimmune dis-
ease (30–33). The demonstration, therefore, that TSAd-defi-
cient T cells produce less IL-2 in vivo suggests a molecular
mechanism that links TSAd deficiency to impaired T cell
death and the development of autoimmunity. Significantly,
however, there are differences in the nature of the autoim-
mune disease in IL-2 and IL-2R–deficient mice versus that
seen in TSAd-deficient mice. IL-2 and IL-2R–deficient
mice do not develop glomerulonephritis but instead de-
velop inflammatory bowel disease and severe autoimmune
hemolytic anemias that are not seen in TSAd-deficient
mice. It is possible that expression of inflammatory bowel
disease and hemolytic anemia requires total or near total ab-
sence of IL-2 signaling, whereas in TSAd-deficient mice
significant IL-2 signal transduction would presumably still
occur. Further, because IL-2 and IL-2R–deficient mice die
at an early age, it could be argued that there is not sufficient
time for the development of glomerulonephritis in these
mice. Another possible explanation for the observed differ-
ences is that in TSAd-deficient mice reduced expression of
other identified TSAd-regulated genes, together with im-
paired expression of IL-2, contributes to phenotype.
Aside from mechanism, these studies highlight how defi-
cient expression of TSAd can lead to the development of
systemic autoimmunity. In this regard, TSAd is set further
apart from other adaptor proteins expressed in T cells whose
deficient expression does not similarly result in autoimmune
disease (43). These studies, therefore, also raise the possibil-
ity that deficient expression of TSAd might be a causative
factor in human autoimmunity. Thus far, loss of function
TSAd polymorphisms associated with human SLE have not
been identified (nor looked for). Interestingly, however, a
promoter polymorphism of TSAd has recently been charac-
terized that results in reduced levels of TSAd expression and
shows a statistically significant association with human mul-
tiple sclerosis (44). Taken together with the findings pre-
sented here, this supports the idea that TSAd may represent
a general susceptibility factor for human autoimmunity.
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